Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 348

The DOI matches its Crossref record; 158 of the 158 references it cites were found in a registry or an index.

Steatotic liver disease

Open access
Israelsen, Mads, Francque, Sven, Tsochatzis, Emmanuel A, Krag, Aleksander·2024·The Lancet

Abstract

Steatotic liver disease is the overarching term for conditions characterised by abnormal lipid accumulation in the liver (liver or hepatic steatosis). Steatotic liver disease encompasses what was previously termed non-alcoholic fatty liver disease (NAFLD), which is now called metabolic dysfunction-associated steatotic liver disease (MASLD). Additionally, steatotic liver disease includes alcohol-related liver disease (ALD) and MetALD, the new classification for the overlap between MASLD and ALD, and rare causes of liver steatosis. Cirrhosis is globally the 11th leading cause of death, and steatotic liver disease has become the leading cause of cirrhosis in the EU and USA. Steatotic liver disease affects around 30% of the global population and is mainly driven by obesity, type 2 diabetes, and alcohol intake, but only a minor proportion with steatotic liver disease progress to cirrhosis. The presence and progression of liver fibrosis led by hepatic inflammation is the main predictor of liver-related death across the entire spectrum of steatotic liver diseases. A combination of recent advancements of widely available biomarkers for early detection of liver fibrosis together with considerable advancements in therapeutic interventions offer the possibility to reduce morbidity and mortality in patients with steatotic liver disease. This Seminar covers the recent reclassification of steatotic liver disease and how it reflects clinical practice and prognosis. For early detection of liver fibrosis, we propose a collaborative diagnostic framework between primary care and liver specialists. Lastly, we discuss current best practices for managing steatotic liver disease, we explore therapeutic targets across the spectrum of steatotic liver diseases, and we review the pipeline of drugs in development for MASLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(24)01811-7

Cites

158 of 158 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 158 references

Research works printed but not linked: 4

  1. Russo, 2024, Advocating for the implementation of the new nomenclature for steatotic liver disease: a call to action for the national associations, J Hepatol, 80, 384, 10.1016/j.jhep.2023.12.011 · doi:10.1016/j.jhep.2023.12.011
  2. Helander, 2016, Standardisation and use of the alcohol biomarker carbohydrate-deficient transferrin (CDT), Clin Chim Acta, 459, 19, 10.1016/j.cca.2016.05.016 · doi:10.1016/j.cca.2016.05.016
  3. Israelsen, 2020, Collagen proportionate area predicts clinical outcomes in patients with alcohol-related liver disease, Aliment Pharmacol Ther, 52, 1728, 10.1111/apt.16111 · doi:10.1111/apt.16111
  4. Karlsen, 2024, The EASL-Lancet Commission on liver health in Europe: prevention, case-finding, and early diagnosis to reduce liver-related mortality, Lancet, 403, 1522, 10.1016/S0140-6736(24)00204-6 · doi:10.1016/s0140-6736(24)00204-6

Cited by

See all 348

Metadata

Authors
Israelsen, M., Francque, S., Tsochatzis, E. A., & Krag, A.
Venue
The Lancet
Publisher
Elsevier BV
Published
2024-11
Volume
404
Issue
10464
Pages
1761-1778
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4403964783
Cited by
348
References
158
FWCI
90.99
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Steatotic liver disease. https://app.cochat.ai/papers/10.1016/s0140-6736(24)01811-7
The paper
Israelsen, M., Francque, S., Tsochatzis, E. A., & Krag, A. (2024). Steatotic liver disease. The Lancet. https://doi.org/10.1016/s0140-6736(24)01811-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.